Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Gilead Sciences to expand global access to HIV medicines

Gilead Sciences to expand global access to HIV medicines

12th July 2011

Gilead Sciences has agreed a number of new licensing arrangements that will help to expand access to treatments for HIV and Aids in the developing world.

New licensing terms have been signed with the India-based Hetero Drugs, Matrix Laboratories, Ranbaxy Laboratories and Strides Arcolab to provide access to three Gilead drugs that are currently in late-stage development.

It means that patients in poorer nations will be able to gain quicker access to the investigational compounds elvitegravir and cobicistat, as well as the Quad single-tablet combination therapy.

Meanwhile, similar licensing terms have also been agreed with the Medicines Patent Pool, making Gilead the first company to enter into such an arrangement with the Unitaid-established body.

Gregg Alton, Gilead's executive vice-president for corporate and medical affairs, said: "Our goal is to ensure that as new Gilead HIV therapies are developed and approved, low-cost versions will be rapidly accessible in developing countries without delay."

Last month, the company entered into a new alliance with Tibotec Pharmaceuticals to create a new combination HIV therapy utilising cobicistat and Prezista.ADNFCR-8000103-ID-800618638-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.